Orthofix Medical Inc. (OFIX) revealed Loss for its fourth quarter of -$29.147 million
The company's bottom line totaled -$29.147 million, or -$0.75 per share. This compares with -$22.174 million, or -$0.59 per share, last year.
The company's revenue for the period rose 7.6% to $215.657 million from $200.415 million last year.
Orthofix Medical Inc. earnings at a glance (GAAP) :
-Earnings: -$29.147 Mln. vs. -$22.174 Mln. last year.-EPS: -$0.75 vs. -$0.59 last year.-Revenue: $215.657 Mln vs. $200.415 Mln last year.
For the fourth quarter, the company posted adjusted income of $0.595 million, lower than $4.310 million, recorded for the same period last year.
Looking ahead, for the full-year 2025, Orthofix Medical expects sales of $818 to $826 million, excluding sales from the discontinued M6 artificial disc product lines and including a negative impact from foreign currency of around $4 million, or 50 basis points, on a reported basis, as compared with the full-year 2024.
For the full-year 2024, the company has registered sales of $799.491 million.
OFIX was down by 6.23 percent at $17.02 in the pre-market trade on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.